1/16/2024 0 Comments Schering pharma![]() Joining forces will allow us to take advantage of each other’s strengths which will for sure drive the research and innovation in these fields.” said Prof. “Endometriosis and uterine fibroids are severe diseases that significantly compromise the health and quality of life of women. 301 Hospital is one of the biggest general hospitals in China and has gained a high reputation in gynaecology and obstetrics research and expert knowledge in treatment of patients suffering from related diseases. Andreas Busch, Member of the Board of Management at Bayer Schering Pharma and Head of Global Drug Discovery. We are looking forward to a successful collaboration.” said Prof. “Working together with the experts from The People’s Liberation Army General Hospital will help us to bring new therapies faster to patients suffering from gynaecological diseases, like endometriosis and uterine fibroids. Combining the strong expertise of the scientists at 301 Hospital and at Bayer Schering Pharma in Women’s Healthcare, the first project will focus on the establishment and analysis of disease models and disease understanding. The joint research programmes will initially be focused on but not limited to gynaecological diseases. Bayer Schering Pharma scientists from the recently established Bayer Schering Pharma Global Drug Discovery-Innovation Center China in Beijing will participate in and coordinate the research projects. ![]() Under the terms of the agreement, 301 Hospital will receive research funding and their scientists will be able to work at Bayer Schering Pharma’s research facilities in Berlin, Germany. The collaboration partners will establish a long-term strategic research partnership in the area of Women’s Healthcare that would benefit patients in China and worldwide. The CEER platform measures the expression and activation of specific cancer pathways using blood or tissue samples.Bayer Schering Pharma AG, Germany, has entered into a research collaboration agreement with The People’s Liberation Army General Hospital (301 Hospital) in Beijing, China. The goal of the deal, which could net Prometheus as much as $160 million, is to develop tools to stratify patients and direct them to the correct drug treatment, and to accelerate the development of new oncology diagnostics and therapeutics. In March, the two companies entered a research collaboration and licensing agreement bringing together Prometheus' oncology diagnostic CEER platform and Bayer's extensive oncology pipeline. ![]() No further financial details of the deal were disclosed. Prometheus will carry out mutational analyses to characterize the presence or absence of mutations in the samples that may be associated with cancer.īayer will pay Prometheus for each mutational analysis it performs, with payment amounts based on the complexity of the analysis. Under the deal, Bayer will provide samples that have been sourced from clinical trials. ![]() Information gleaned from the new agreement may lead to better patient stratification in clinical studies and hasten the development of new cancer diagnostics and treatments, Prometheus said in a statement. NEW YORK (GenomeWeb News) – Prometheus Laboratories and Bayer Schering Pharma today said they have executed an oncology-focused mutational analyses services agreement, building on a deal reached between the two parties earlier this year. Advances in Clinical Genomics Profiling. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |